徐州多久做四维彩超理想徐州四维彩超检查什么,徐州怀孕几个月开始可以做四维彩超,徐州双胞胎四维彩超的更佳时间,徐州无痛胃镜检查一次多少钱,徐州孕29周还能做四维彩超吗,徐州孕妇四维b超要做吗,徐州四维彩超一定要做吗多少钱

The Bureau of Transportation Statistics released preliminary data on Monday, which shows U.S. airlines carried almost twice as many passengers in June than in May. According to the news release, BTS said data collected showed that 16.3 million passengers flew on large airlines in June, up from 8.4 million on all U.S. airlines in May.The BTS said airlines carried 80% fewer passengers in June than it did exactly one year ago.The data was by 20 airlines that carry 90% of the passengers, the agency said."June 2020 was the second consecutive month that the annual decrease in the number of U.S. airline passengers was less than annual change in the previous month," BTS reported.According to the agency, preliminary data showed a 77% decline in domestic passengers between June 2019 to June 2020 following more substantial annual reductions in May (88%) and April (96%).Preliminary data showed that international passengers on U.S. airlines declined 96% from June 2019 to June 2020, following annual decreases of 99% in April and 98% in May, the agency said.BTS says final U.S. airline traffic reports for June will be released on Sept. 11. International data by origin and destination, which is under a six-month confidentiality restriction, will be released on Dec. 10, the agency said. 1297

The devastation brought about by this hurricane season creates a new set of headaches for President Donald Trump and an already overwhelmed Congress -- and underscores the urgent need to resolve the financial crisis that had battered Puerto Rico and the US Virgin Islands before the recent storms and floods arrived.The President and Congress can no longer ignore their duty to rescue millions of Americans living in our tropical territories. The standard range of the Federal Emergency Management Agency and other disaster recovery programs will cover a good chunk of the storm damage, but the need for financial rebuilding is every bit as necessary as the new homes, roads and power grid the islands need. 730

The colors of an autumn afternoon can be serene, brilliant and breathtaking.“As the days start getting shorter and the nights get longer, that's the cue that the trees get to change the foliage,” said climate scientist Astrid Caldas.That foliage requires a delicate dance of temperature and moisture to produce fall colors. It’s a dance potentially now in jeopardy due to climate change.“Because these things -- temperature and precipitation, rainfall -- are being affected, changed by climate, then the fall foliage can really get affected,” said Caldas, who is a senior climate scientist at the Union of Concerned Scientists, a nonprofit science organization.She said long-term shifting temperature trends and more rain will be disruptive to fall foliage in certain parts of the country.“We are seeing extreme precipitation increase, particularly in the Northeast and the Midwest,” Caldas said.That precipitation was evident in Minnesota, where people found themselves caught off-guard this year by an unusually early snowfall."I had to completely disassemble my fall leaf clean-up box and make sure my plow is still working,” said Greg Futchi, who is a landscape contractor. “We usually get all the leaves down before we see some snow, but not this year."All of that added moisture can lead to a shorter fall foliage season, Caldas said. Yet, repeated and ongoing droughts, like those seen in the western U.S., also bring their own set of problems to autumn leaves.“When it’s very dry, the colors get a little more muted also,” Caldas said. “So, drought can really kind of change completely the setup.”Scientists add that climate change isn’t just going to affect the ways leaves change their colors during the fall. It’s also going to potentially affect where those trees grow in the first place.“When the conditions start changing --like it's starting to get warmer further and further north--well, that's also a possibility that species are going to start migrating farther north,” Caldas said. “So, as different trees start moving to different areas, then the colors may change because the color depends on the tree.”That may mean having to travel farther north to see stunning red maples. It is a change that will be hard to stop unless action is taken on a global scale.“In the long run, if the countries and the whole world is not committed to really reducing emissions and changing to renewables and making that complete change, then it's going to be very hard for us not to see very drastic changes, because small changes are already happening,” Caldas said.Those changes are now encroaching on a time-honored spectacle, courtesy of Mother Nature. 2667

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The day after a gunman who spewed anti-Semitic rhetoric allegedly?killed 11 congregants in a Pittsburgh synagogue, thousands mourned the dead, said their names out loud and proclaimed that hate wasn't welcome in their city.The crowd at the Jewish Family and Community Services of Pittsburgh's interfaith gathering and vigil spilled out of the Soldiers & Sailors Memorial Hall & Museum. Many stood in the drizzle outside during the ceremony.Less than two miles away, agents filed in and out of the site of the massacre: Tree of Life Synagogue, which houses three congregations. Authorities said Robert Bowers stormed the building early Saturday and killed the congregants gathered for Shabbat services in what the Anti-Defamation League has called the deadliest attack on the Jewish community in US history.At Sunday's service, the rabbis of the three congregations embraced after tearful tributes. Christian and Muslim leaders pledged to stand with members of the Jewish community. 1007